2017 Article Archive

First-in-class drug holds promise for therapy-resistant breast cancer


UT Southwestern Simmons Cancer Center researchers have shown that a first-in-class molecule can prevent breast cancer growth when traditional therapies stop working.

Study answers why ketamine helps depression, offers target for safer therapy


UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine’s rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.

The link between fat tissue and disease


Body fat can seem mysterious and confounding, but Dr. Philipp E. Scherer aims to unravel those mysteries – especially in regard to fat’s relationship with disease.

Top 5 news articles of 2017


Stories below from UT Southwestern’s Peter O’Donnell Jr. Brain Institute, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical School, and Obstetrics and Gynecology Department garnered the most mouse clicks during 2017.

UTSW police show a heart for the homeless


The inability to lend a tangible hand to homeless individuals had long bothered UTSW Police Cpl. Phillip Starr. That led him and other officers to assemble and hand out basic comfort kits for those in need.

How to cook up some healthy, hearty holiday foods


Learn how to make healthier versions of some favorite holiday foods – turkey, sweet potatoes, desserts, and more.

School of Health Professions graduates 124 at commencement


School of Health Professions graduates 124 at commencement

Sweet tips on how to limit sugar during the holidays


Tips on how to cut back on sugars during the holidays.

FDA-approved high blood pressure drug extends life span in roundworms


An FDA-approved drug to treat high blood pressure seems to extend life span in worms via a cell signaling pathway that may mimic caloric restriction.

New class of anti-cancer drug effective against kidney cancer


A novel drug belonging to a new class of medicines called HIF-2 inhibitors show promise in treating metastatic kidney cancer.